EFFECTS ON HEALTH AND COSTS OF DELAYED IMPLEMENTATION OF THE ONCOTYPE DX® TEST FOR ELIGIBLE BREAST CANCER PATIENTS

被引：0
|
作者：
Appelberg, K. [1 ]
Wilking, N. [2 ]
Levin, L. A. [1 ]
机构：
[1] Linkoping Univ, Linkoping, Sweden
[2] Karolinska Inst, Solna, Sweden
来源：
VALUE IN HEALTH | 2024年 / 27卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE93
引用
收藏
页码：S72 / S72
页数：1
相关论文
共 50 条
  • [31] Oncotype DX in Bilateral Synchronous Primary Invasive Breast Cancer
    Gunthner-Biller, M.
    Stempel, M.
    Patil, S.
    King, T.
    ANNALS OF SURGICAL ONCOLOGY, 2015, 22 : S68 - S68
  • [32] Adjuvant Chemotherapy for Patients with Breast Cancer Based on Clinical and Evolving Oncotype DX Criteria
    Zekri, Jamal
    Al-Foheidi, Meteb
    Alata, Maaz
    Zabani, Reem
    Rasmy, Ayman
    BREAST CARE, 2020, 15 (06) : 642 - 647
  • [33] Oncotype DX in Bilateral Synchronous Primary Invasive Breast Cancer
    Maria Karsten
    Michelle Stempel
    Julia Radosa
    Sujata Patil
    Tari A. King
    Annals of Surgical Oncology, 2016, 23 : 471 - 476
  • [34] Oncotype DX in Bilateral Synchronous Primary Invasive Breast Cancer
    Karsten, Maria
    Stempel, Michelle
    Radosa, Julia
    Patil, Sujata
    King, Tari A.
    ANNALS OF SURGICAL ONCOLOGY, 2016, 23 (02) : 471 - 476
  • [35] OUR FIRST EXPERIENCE OF ONCOTYPE DX IN EARLY BREAST CANCER
    Khawaja, S.
    Sharaiha, Y.
    Pitcher, S.
    Whelan, S.
    Brinkworth, E.
    Pudney, D.
    Moe, M.
    Rolles, M.
    Bertelli, G.
    Holt, S.
    ANNALS OF ONCOLOGY, 2011, 22 : 46 - 46
  • [36] NSABP study confirms Oncotype DX predicts chemotherapy benefit in breast cancer patients
    不详
    ONCOLOGY-NEW YORK, 2006, 20 (07): : 789 - 790
  • [37] Implementation of surgeon-initiated Oncotype DX ordering among patients with breast cancer to reduce chemotherapy wait times.
    Losk, Katya
    Freedman, Rachel A.
    Lin, Nancy U.
    Golshan, Mehra
    Lester, Susan
    Pochebit, Stephen
    Natsuhara, Kelsey
    Camuso, Kristen
    King, Tari A.
    Bunnell, Craig A.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (08)
  • [38] Disparities in compliance with the Oncotype DX breast cancer test in the United States: A National Cancer Data Base assessment
    Kozick, Zachary
    Hashmi, Ammar
    Dove, James
    Hunsinger, Marie
    Arora, Tania
    Wild, Jeffrey
    Shabahang, Mohsen
    Blansfield, Joseph
    AMERICAN JOURNAL OF SURGERY, 2018, 215 (04): : 686 - 692
  • [39] Factors associated with chemotherapy benefit in breast cancer patients with midrange Oncotype DX breast recurrence scores
    Cheng, Ran
    Wang, Zhongzhao
    Kong, Xiangyi
    Wang, Jing
    Fang, Yi
    Qi, Liqiang
    CANCER LETTERS, 2021, 503 : 213 - 219
  • [40] Cost effectiveness of oncotype Dx for early stage breast cancer; under National Health Insurance
    Kim, Y.
    Kim, K. E.
    Ju, Y. W.
    Lee, E.
    Lee, H. B.
    Moon, H. G.
    Noh, D. Y.
    Han, W.
    EUROPEAN JOURNAL OF CANCER, 2018, 92 : S31 - S31
12345